Affymetrix and NimbleGen Systems Enter into Licensing Agreement
Affymetrix Inc. and NimbleGen Systems Inc. have announced that NimbleGen has obtained a non-exclusive, worldwide license to a number of Affymetrix patents covering the manufacture, use and sales of nucleic acid microarrays and related products and services in the research field.
"This licensing agreement with NimbleGen follows from a commercial relationship and enables both companies to better serve customers within the growing microarray market," said Alan Sherr, vice president and chief counsel for Licensing at Affymetrix.
"Since the inception of our licensing program, Affymetrix has signed many agreements that validate our position as the clear market innovator and leader. We look forward to the continued expansion of this program."
"This license is a major milestone in NimbleGen's evolution as a company, and part of a fundamental expansion of our commercial strategy," said Stan Rose, Ph.D., president and CEO of NimbleGen.
"Our intent is to expand dramatically the ability of scientists to access NimbleGen products and services."